Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash & Equivalents (2016 - 2025)

Moleculin Biotech's Cash & Equivalents history spans 10 years, with the latest figure at $8.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $8.9 million for Q4 2025, up 107.53% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (up 107.53% YoY), and the annual figure for FY2025 was $8.9 million, up 107.53%.
  • Cash & Equivalents for Q4 2025 was $8.9 million at Moleculin Biotech, up from $6.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $86.3 million in Q1 2021 to a low of $4.3 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $28.4 million (2023), against an average of $36.0 million.
  • The sharpest move saw Cash & Equivalents soared 640.84% in 2021, then plummeted 81.83% in 2024.
  • Year by year, Cash & Equivalents stood at $70.9 million in 2021, then plummeted by 39.15% to $43.1 million in 2022, then tumbled by 45.42% to $23.6 million in 2023, then plummeted by 81.83% to $4.3 million in 2024, then surged by 107.53% to $8.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $8.9 million, $6.7 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.